Reem Karmali

Grants

Grants per year 2013 2015 2018 2019 2020 2023 2024 2029

• 19 Active
• 22 Finished

Grants per year

Search results

• Active

  Prot #M-2023-401: A Prospective, Observational, Long-Term Follow-up Study for Subjects who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study

  Karmali, R. (PD/PI)

  Miltenyi Biomedicine GmbH

  1/7/25 → 1/7/28

  Project: Research project

• Prot #M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

  Karmali, R. (PD/PI)

  AbbVie Inc.

  11/22/24 → 11/22/27

  Project: Research project

• Prot #NU 23H05: Phase II, Single arm, Open label, study of the combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients

  Karmali, R. (PD/PI)

  Merck Sharp & Dohme LLC

  9/23/24 → 9/23/27

  Project: Research project

• Prot #GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing The Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA

  Karmali, R. (PD/PI)

  Genentech, Inc

  7/18/24 → 5/31/29

  Project: Research project

• Prot #CRG‐022‐101: An Open‐label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG‐022, a CD22‐Directed Autologous Chimeric Antigen Receptor (CAR) T‐cell Therapy in Patients With Relapsed/Refractory Large B‐Cell Lymphoma After CD19‐Dire

  Karmali, R. (PD/PI)

  Novella Clinical, LLC, CARGO Therapeutics, Inc.

  5/24/24 → 4/30/26

  Project: Research project

• Prot #BTCRC-LYM20-463: A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

  Karmali, R. (PD/PI)

  Hoosier Cancer Research Network, Inc., Epizyme, Inc.

  4/26/24 → 4/26/27

  Project: Research project

• Prot #SC291-101: A Phase 1 Study Evaluating SC291, a Hypoimmune Allogeneic CD19-Directed CAR T Cell Therapy, in Relapsed and/or Refractory B-Cell Malignancies (ARDENT)

  Karmali, R. (PD/PI)

  PPD Development, Sana Biotechnology, Inc.

  4/9/24 → 4/9/27

  Project: Research project

• Prot #KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleuce

  Karmali, R. (PD/PI)

  ICON Clinical Research Limited, Kite Pharma, Inc.

  1/22/24 → 1/22/27

  Project: Research project

• Prot #KT‐US‐484‐0136: An Adaptive Phase 3, Randomized, Open‐Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First‐Line Therapy in Subjects with High‐Risk Large B‐Cell Lymphoma (ZUMA

  Karmali, R. (PD/PI)

  ICON Clinical Research Limited, Kite Pharma, Inc.

  11/7/23 → 11/7/26

  Project: Research project

• Prot #KT‐US‐471‐0140: Expanded Access Study for the Treatment of Patients with Commercially Out‐of‐Specification Axicabtagene Ciloleuce

  Karmali, R. (PD/PI)

  ICON Clinical Research Limited, Kite Pharma, Inc.

  9/14/23 → 9/14/26

  Project: Research project

• Y24-28 Carryforward

  Johnson, J. L. P. (Other), Karmali, R. (Other), Kirsammer, G. (Other) & Lorch, J.H.-M. (Other)

  National Cancer Institute

  8/1/23 → 7/31/25

  Project: Research project

• Prot #NU MSK22H05: Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)

  Karmali, R. (PD/PI)

  Memorial Sloan Kettering Cancer Center, BeiGene Ltd.

  3/20/23 → 3/20/26

  Project: Research project

• Prot #M-2018-344: A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Dif

  Karmali, R. (PD/PI)

  Parexel, Miltenyi Biomedicine GmbH

  8/12/22 → 8/12/25

  Project: Research project

• Prot #STU00215064: NU 20H09: Phase II, Single-arm, Open-label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-cell Therapy in Aggressive B-cell Non-Hodgkin's Lymphoma

  Karmali, R. (PD/PI)

  BeiGene Switzerland GmbH

  12/21/21 → 12/21/27

  Project: Research project

• Prot #JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release

  Karmali, R. (PD/PI)

  DrugDev Inc., Juno Therapeutics, Inc.

  2/3/21 → 1/30/26

  Project: Research project

• Prot #NU MSK19H03: A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)

  Karmali, R. (PD/PI)

  Memorial Sloan Kettering Cancer Center

  9/17/20 → 9/17/26

  Project: Research project

• Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)

  Karmali, R. (PD/PI)

  ICON Clinical Research, LLC, Celgene Corporation

  7/27/20 → 7/27/26

  Project: Research project

• Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR

  Karmali, R. (PD/PI)

  ICON Clinical Research, LLC, Celgene Corporation

  10/21/19 → 10/21/25

  Project: Research project

• Prot #X34001/NU 18H02: A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B cell Lymphoma (DLBCL)

  Karmali, R. (PD/PI)

  GMA Research Corporation, Millennium Pharmaceuticals, Inc.

  2/19/19 → 2/19/27

  Project: Research project

• Finished

  Prot #CX-659-401: A Phase 2 Study of Mivavotinib in Biomarker-Defined Subgroups of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

  Karmali, R. (PD/PI)

  Calithera Biosciences, Inc.

  9/7/22 → 3/31/23

  Project: Research project

• Prot #TAK-007-2001: A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  Karmali, R. (PD/PI)

  PPD Investigator Services, LLC, Takeda Development Center Americas, Inc.

  6/10/22 → 6/10/25

  Project: Research project

• Prot #KT-US-471-0119: A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)

  Karmali, R. (PD/PI)

  Gilead Sciences, Inc, Kite Pharma, Inc.

  10/14/20 → 10/14/23

  Project: Research project

• Prot #RPM-CART-001: An Observational Study to Evaluate a Temperature Monitoring Device in Subjects Receiving CAR-T Therapy

  Karmali, R. (PD/PI)

  Celgene Corporation

  9/28/20 → 9/28/23

  Project: Research project

• Prot #NDS-NHL-001: A Global, Non-Interventional, Retrospective, Multi-Center Study To Generate Real-World Evidence Of Treatment Outcomes In Subjects With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  Karmali, R. (PD/PI)

  Quintiles, Inc., Celgene Corporation

  9/18/19 → 9/18/24

  Project: Research project

• Prot #NEER-01: Network for Enigmatic Exceptional Responders to Cancer Treatment - The Cure is NEER

  Karmali, R. (PD/PI)

  Takeda Pharmaceuticals U.S.A., Inc., Millennium Pharmaceuticals, Inc.

  6/12/19 → 6/12/22

  Project: Research project